Document Detail


Predicting haloperidol treatment response in chronic schizophrenia.
MedLine Citation:
PMID:  8888364     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The study attempted to identify pretreatment characteristics of chronic schizophrenic patients that would predict remission in psychosis and amount of clinical improvement after treatment with haloperidol. Thirty-five acutely relapsed schizophrenic patients were entered into a blind 6-week treatment protocol. Pretreatment measures were assessed for prediction of both remission status (dichotomous) and for correlations with change in psychopathology (continuous). Later age of onset and higher plasma homovanillic acid values were significant predictors of remission status (model 1). However, higher cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol, as well as indices of normal neurodevelopment, predicted larger changes in psychopathology. The results indicate that the definition of drug response determines the predictive variables. Dopaminergic activity seems to relate to the ability to reach remission, while noradrenergic activity relates to symptom intensity and reduction. In addition to catecholamine activity, neurodevelopmental changes determine response to haloperidol.
Authors:
D P van Kammen; M E Kelley; J K Yao; M W Gilbertson; J A Gurklis; T Inosaka; H Saito; J L Peters; M Sato
Related Documents :
1332094 - Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizoph...
8075904 - The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patien...
4092484 - The comprehension and production of complex syntax in schizophrenia.
8029314 - Negative difference (nd), an erp marker of stimulus relevance: different lateral asymme...
2660134 - Pancreatic duct dilatation after secretin stimulation in patients with pancreas divisum.
22034564 - Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile i...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Psychiatry research     Volume:  64     ISSN:  0165-1781     ISO Abbreviation:  Psychiatry Res     Publication Date:  1996 Aug 
Date Detail:
Created Date:  1997-02-21     Completed Date:  1997-02-21     Revised Date:  2008-04-17    
Medline Journal Info:
Nlm Unique ID:  7911385     Medline TA:  Psychiatry Res     Country:  IRELAND    
Other Details:
Languages:  eng     Pagination:  47-58     Citation Subset:  IM    
Affiliation:
Department of Veterans Affairs Medical Center, Pittsburgh, PA 15206-1297, USA. dpvk@pitts-hghlnd.va.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antipsychotic Agents / therapeutic use*
Chronic Disease
Haloperidol / therapeutic use*
Homovanillic Acid / blood
Humans
Male
Methoxyhydroxyphenylglycol / cerebrospinal fluid
Middle Aged
Prognosis
Psychiatric Status Rating Scales
Schizophrenia / blood,  diagnosis,  drug therapy*
Schizophrenic Psychology*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
R01-MH-44841/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 306-08-1/Homovanillic Acid; 52-86-8/Haloperidol; 534-82-7/Methoxyhydroxyphenylglycol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neurocognitive function in alcoholic, schizophrenic, and dually diagnosed patients.
Next Document:  Reliability and validity of a scale to measure change in persons with compulsive buying.